{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:29Z","timestamp":1793367149358,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["242102310334"],"award-info":[{"award-number":["242102310334"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejso.2026.112108","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:59:24Z","timestamp":1788278364000},"page":"112108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring heterogeneity in survival benefit of neoadjuvant therapy for triple-negative breast cancer using causal survival forests"],"prefix":"10.1016","volume":"52","author":[{"given":"Wenjing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-2957","authenticated-orcid":false,"given":"Xiaocan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2026.112108_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ejso.2026.112108_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41571-018-0001-7","article-title":"Triple-negative breast cancers - a panoply of cancer types","volume":"15","author":"Pareja","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112108_bib3","doi-asserted-by":"crossref","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13. United States2007. p. 4429\u20134434.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"10.1016\/j.ejso.2026.112108_bib4","doi-asserted-by":"crossref","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 39. United States2021. p. 1485\u20131505.","DOI":"10.1200\/JCO.20.03399"},{"issue":"21","key":"10.1016\/j.ejso.2026.112108_bib5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2026.112108_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112108_bib7","doi-asserted-by":"crossref","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33. United States2015. p. 13\u201321.","DOI":"10.1200\/JCO.2014.57.0572"},{"issue":"7","key":"10.1016\/j.ejso.2026.112108_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2026.112108_bib9","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112108_bib10","first-page":"2184","article-title":"Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence","volume":"45","author":"Dahabreh","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"469","key":"10.1016\/j.ejso.2026.112108_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1198\/016214504000001880","article-title":"Causal inference using potential outcomes: design, modeling, decisions","volume":"100","author":"Rubin","year":"2005","journal-title":"J Am Stat Assoc"},{"issue":"26","key":"10.1016\/j.ejso.2026.112108_bib12","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1002\/sim.9154","article-title":"A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint","volume":"40","author":"Hoogland","year":"2021","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.112108_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cpt.1907","article-title":"From real-world patient data to individualized treatment effects using machine learning: current and future methods to address underlying challenges","volume":"109","author":"Bica","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ejso.2026.112108_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300041","article-title":"Individualized treatment effect prediction with machine learning - Salient considerations","volume":"3","author":"Desai","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejso.2026.112108_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hernan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112108_bib16","first-page":"290","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.112108_bib17","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fonc.2019.01068","article-title":"Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejso.2026.112108_bib18","doi-asserted-by":"crossref","unstructured":"Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. 7. United States2016. p. 31079\u201331087.","DOI":"10.18632\/oncotarget.9075"},{"issue":"4","key":"10.1016\/j.ejso.2026.112108_bib19","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2589-7500(23)00267-4","article-title":"Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model): a modelling study","volume":"6","author":"Montgomery-Csob\u00e1n","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.ejso.2026.112108_bib20","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"issue":"2","key":"10.1016\/j.ejso.2026.112108_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating heterogeneous treatment effects with right-censored data via causal survival forests","volume":"85","author":"Cui","year":"2023","journal-title":"J R Stat Soc, Ser B Stat Methodol"},{"issue":"11","key":"10.1016\/j.ejso.2026.112108_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.joca.2022.08.010","article-title":"Causal inference from observational data and target trial emulation","volume":"30","author":"Jafarzadeh","year":"2022","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.ejso.2026.112108_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jclinepi.2017.10.021","article-title":"The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects","volume":"94","author":"van Klaveren","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"549","key":"10.1016\/j.ejso.2026.112108_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/01621459.2024.2393466","article-title":"Evaluating treatment prioritization rules via rank-weighted average treatment effects","volume":"120","author":"Yadlowsky","year":"2025","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejso.2026.112108_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The predictive approaches to treatment effect heterogeneity (PATH) statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejso.2026.112108_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2026.112108_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/0003-4819-149-10-200811180-00009","article-title":"Assessing the value of risk predictions by using risk stratification tables","volume":"149","author":"Janes","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejso.2026.112108_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jclinepi.2021.01.009","article-title":"Clinical prediction models: diagnosis versus prognosis","volume":"132","author":"van Smeden","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejso.2026.112108_bib29","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2026.112108_bib30","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112108_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers","author":"Han","year":"2022","journal-title":"Korean J Radiol 23 Korea (South)"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:45:24Z","timestamp":1793364324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326007274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0748798326007274"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112108","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring heterogeneity in survival benefit of neoadjuvant therapy for triple-negative breast cancer using causal survival forests","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112108"}}